Table I.
Association between FBLN5 expression and clinicopathological features.
| FBLN5 expression | ||||
|---|---|---|---|---|
| Groups | No. | Low level | High level | P-value |
| Age (years) | 0.024 | |||
| <55 | 74 | 23 | 51 | |
| ≥55 | 85 | 42 | 43 | |
| FIGO stage | 0.244 | |||
| I+II | 35 | 11 | 24 | |
| III+IV | 120 | 52 | 68 | |
| CA125 (U/ml) | 0.868 | |||
| <600 | 64 | 27 | 37 | |
| ≥600 | 87 | 35 | 52 | |
| Ascites (ml) | 0.502 | |||
| <1,000 | 66 | 24 | 42 | |
| ≥1,000 | 84 | 36 | 48 | |
| Omentum metastasis | 0.040 | |||
| Negative | 54 | 16 | 38 | |
| Positive | 101 | 48 | 53 | |
| Lymph node metastasis | 0.566 | |||
| Negative | 41 | 11 | 30 | |
| Positive | 22 | 8 | 14 | |
| Recurrence | 0.008 | |||
| No | 28 | 5 | 23 | |
| Yes | 97 | 45 | 52 | |
| OS (years) | 0.016 | |||
| <48 | 79 | 40 | 39 | |
| ≥48 | 80 | 25 | 55 | |
FBLN5, fibulin-5; FIGO, International Federation of Gynecology and Obstetrics; CA125, cancer antigen 125; OS, overall survival.